NCT03596567已完成1 期
A PHASE 1, OPEN-LABEL, SINGLE DOSE, PARALLEL GROUP STUDY TO EVALUATE THE PHARMACOKINETICS OF GLASDEGIB (PF-04449913) IN SUBJECTS WITH IMPAIRED RENAL FUNCTION
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 18
- 试验地点
- 3
- 主要终点
- Maximum Observed Plasma Concentration (Cmax)
研究概览
简要总结
The goal of this study is to administer single dose (100 mg) glasdegib tablet to subjects with normal, moderate and severe renal impairment and estimate the effect, if any, of this renal impairment on glasdegib pharmacokinetics.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy female subjects of non child bearing potential and/or male subjects who, at the time of screening, are between the ages of 18 and 75 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG or clinical laboratory tests.
- •Female subjects of nonchildbearing potential must meet at least 1 of the following criteria:
- •Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; with a serum follicle stimulating hormone (FSH) level confirming the postmenopausal state;
- •Have undergone a documented hysterectomy and/or bilateral oophorectomy;
- •Have medically confirmed ovarian failure. All other female subjects (including females with tubal ligations) are considered to be of childbearing potential.
- •Body mass index (BMI) of 17.5 to 40 kg/m2; and a total body weight >50 kg (110 lb).
- •Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study.
- •Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •Subjects with Normal Renal Function will Need to Meet the Following Criteria in addition -
- •Normal renal function, eGFR=>90 mL/min, based on the MDRD equation.
- •Matched for age (+/-10years) weight +/-15kg, and gender to subjects in the impaired renal function groups
- •Subjects with Impaired Renal Function will Need to Meet the Following Criteria in Addition to Those Above
- •Good general health commensurate with the population with chronic kidney disease (renal impairment). 'Health' is defined as no clinically relevant abnormalities (with the exception of hypertension, diabetes mellitus, hyperparathyroidism, ischemic heart disease, etc. as long as, in the opinion of the investigator, the subject is medically stable, is on a stable drug regimen and can abide by the meals and dietary restrictions outlined in protocol identified by a detailed medical history, full physical examination, measurement of pulse rate and 12 lead ECG as well as clinical laboratory tests (except serum creatinine and eGFR).
- •Stable drug regimen defined as not starting a new drug or changing dosage within seven days or five half lives (whichever is longer) before dosing the study drug.
- •Any form of renal impairment except acute nephritic syndrome (subjects with history of previous nephritic syndrome but in remission can be included).
- •Meet one of the following eGFR criteria during the screening period based on the MDRD equation:
- •Moderate renal impairment: eGFR 30 mL/min and <60 mL/min, or
- •Severe renal impairment: eGFR <30 mL/min, but not requiring hemodialysis. For subjects in all groups, the values of serum creatinine obtained at the two screening visits should not be more than 20% different.
排除标准
- •Any condition possibly affecting drug absorption (eg, gastrectomy, achlorhydria).
- •Renal allograft recipients
- •Urinary incontinence without catheterization.
- •Concurrent use of any of the following food or drugs known to inhibit CYP3A4 (consult the Sponsor if in doubt whether a food or a drug falls into any of the above categories) within 7 days or 5 half lives (whichever is longer) prior to the dose of glasdegib, until the completion of the last PK sample collection.
- •Concurrent use of any of the following food or drugs known to induce CYP3A4 (consult the Sponsor if in doubt whether a food or a drug falls into any of the above categories) within 12 days or 5 half lives (whichever is longer) prior to the first dose of trial medication until the completion of the last PK sample collection.
- •Pregnant female subjects; breastfeeding female subjects; fertile male subjects who are unwilling or unable to use two highly effective methods of contraception as outlined in this protocol for the duration of the study and for at least 90 days after the last dose of investigational product and, refrain from sperm donation for the duration of the Study and for at least 90 days after the last dose of investigational product.
- •Subjects with ANY of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:
- •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level > upper limit of normal (ULN);
- •Total bilirubin level 1.5 × ULN; subjects with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is not greater than 0.5 mg/dL.
- •For subjects with renal impairment, the following important additional criteria are:
- •Subjects with other clinically significant disease that may affect the safety of the subject or that may affect the pharmacokinetics of glasdegib (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). Subjects with any significant hepatic, cardiac, or pulmonary disease or subjects who are clinically nephrotic. Hypertension, diabetes mellitus, hyperparathyroidism, ischemic heart disease, etc is not cause for exclusion as long as the subject is medically stable and any drugs that are administered for these conditions are not expected to interfere with the pharmacokinetics of glasdegib.
- •Screening blood pressure =>180mm Hg (systolic) or>=110 mm Hg (diastolic), following at least 5 minutes of supine rest. If initial blood pressure (BP) is 180 mm Hg (systolic) or 110 mm Hg (diastolic), the BP should be repeated two more times and the average of the three BP values should be used to determine the subject's eligibility.
- •Screening supine 12 lead ECG demonstrating QTcF >470 msec or a QRS interval >120 msec. If initial QTcF exceeds 470 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTcF or QRS values should be used to determine the subject's eligibility.
研究组 & 干预措施
Moderate Renal Impairment Group
Experimental
Subjects with estimated glomerular filtration rate (eGFR) of => 30ml/min and < 60 ml/min
干预措施: Glasdegib single 100 mg dose in moderate renal impairment subjects (Drug)
Normal Renal Function Group
Experimental
Subjects with estimated glomerular filtration rate (eGFR) of => 90 ml/min
干预措施: Glasdegib single 100 mg dose in normal healthy subjects (Drug)
Severe Renal Impairment Group
Experimental
Subjects with estimated glomerular filtration rate (eGFR) of < 30 ml/min and not requiring dialysis
干预措施: Glasdegib single 100 mg dose in severe renal impairment subjects (Drug)
结局指标
主要结局
Maximum Observed Plasma Concentration (Cmax)
时间窗: 6 days
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]
时间窗: 6 days
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
次要结局
- ECGs(34 days)
- pH/Urinalysis Lab Panel(34 days)
- Monocytes/Hematology Lab Panel(34 days)
- Hemoglobin /Hematology Lab Panel(34 days)
- Basophils/Hematology Lab Panel(34 days)
- Lymphocytes/Hematology Lab Panel(34 days)
- Total Protein/Chemistry Lab Panel(34 days)
- ALT/Chemistry Lab Panel(34 days)
- Alkaline Phosphate/Chemistry Lab Panel(34 days)
- Sodium/Chemistry Lab Panel(34 days)
- Potassium/Chemistry Lab Panel(34 days)
- Chloride/Chemistry Lab Panel(34 days)
- Creatinine/Chemistry Lab Panel(34 days)
- AST/Chemistry Lab Panel(34 days)
- Glucose/Chemistry Lab Panel(34 days)
- Blood Pressure(34 days)
- Pulse Rate(34 days)
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).(34 days)
- PR/ECGs(34 days)
- Hematology Lab Panel(34 days)
- BUN /Chemistry Lab Panel(34 days)
- Albumin/Chemistry Lab Panel(34 days)
- MCHC/Hematology Lab Panel(34 days)
- WBC count/Hematology Lab Panel(34 days)
- Total neutrophils/Hematology Lab Panel(34 days)
- Eosinophils/Hematology Lab Panel(34 days)
- Calcium/Chemistry Lab Panel(34 days)
- Total Bilirubin/Chemistry Lab Panel(34 days)
- Uric acid/Chemistry Lab Panel(34 days)
- Magnesium/Chemistry Lab Panel(34 days)
- QTc/ECGs(34 days)
- QRS/ECGs(34 days)
- Glucose/Urinalysis Lab Panel(34 days)
- Protein/Urinalysis Lab Panel(34 days)
- Blood/Urinalysis Lab Panel(34 days)
- Ketones/Urinalysis Lab Panel(34 days)
- Nitrites/Urinalysis Lab Panel(34 days)
- Leukocyte /Urinalysis Lab Panel(34 days)
- Urobilinogen/Urinalysis Lab Panel(34 days)
- Urine bilirubin/Urinalysis Lab Panel(34 days)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic ImpairmentHypertensionNCT05961397AstraZeneca20
已完成
1 期
A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7)Renal ImpairmentNCT03159416The Medicines Company31
已完成
1 期
A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic ImpairmentChronic Hepatitis CNCT01817985Gilead Sciences33
已完成
1 期
A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy VolunteersNASHNCT03207425Enanta Pharmaceuticals, Inc29
进行中（未招募）
1 期
A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver DysfunctionModerate Hepatic ImpairmentSevere Hepatic ImpairmentHealthy VolunteersNCT05224609Pfizer16